Akademik Veri Yönetim Sistemi
EUROPEAN JOURNAL OF THERAPEUTICS, 2025 (ESCI, TRDizin)
Objective: Acute lung injury (ALI) is caused by an imbalance between pro-inflammatory and anti-inflammatory cytokines as well as oxidants and antioxidants. These imbalances and the resulting hypoxemia can affect various cells, especially the myocardium. Auraptene is known for its antioxidant and anti-inflammatory effects. The aim of this study was to determine whether auraptene can be used to treat both ALI and myocardial injury secondary to ALI. Methods: The study was conducted with 24 ALI and 16 sham rats. Zero hour:Blood sampling, followed by the 150 mu l saline (sham) or LPS (ALI) intratracheally. 24. Hour:Blood and organs ampling, followed by euthanize of the animals. The collected material was used for serum TNF-alpha, troponin T (TnT), pro-brain natriuretic peptide (BNP) and histologic examinations. Results: TNF-alpha levels were significantly lower in the LPS+auraptene group than in the LPS group (p=0.007). Increased pulmonary lymphocyte, neutrophil, hemorrhage and, fibroblast and histiocyte scores in LPS-induced ALI were significantly reduced by the use of auraptene (p<0.001, p=0.003, p=0.006 and, p=0.001, respectively). The BNP and TnT values in the LPS auraptene group were significantly lower compared to the LPS group (p=0.046 and, p=0.045, respectively). Histologically, cardiac degeneration, disorganization, congestion and inflammation scores were significantly lower in the LPS+Auraptene group than in the LPS group (p=0.005, p=0.006, p=0.002 and, p=0.036, respectively). Conclusions: This study showed that ALI can lead to myocardial injury. Our results also suggest that auraptene, which suppresses inflammation, can be used to treat both ALI and myocardial injury secondary to ALI.